Priming with FAKi monotherapy revealed a similar increase in the proportion of cells in S-G2-M phase compared to control (Fig. 5, B and C), which may be due to direct effects of FAK inhibition on KPC tumor cells and indirect effects via changes in the tumor ECM architecture. The gene discussed is PTK2; the disease is neoplasm.